+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "CAR T Cell"

From
From
From
From
From
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025 - Product Thumbnail Image

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025

  • Drug Pipelines
  • March 2025
  • 450 Pages
  • Global
From
Thyroid Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Thyroid Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • August 2024
  • 180 Pages
  • Global
From
From
From
Advanced liver cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Advanced liver cancer - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 180 Pages
  • Global
From
CAR-T - Pipeline Insight, 2024 - Product Thumbnail Image

CAR-T - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 450 Pages
  • Global
From
Metastatic Liver Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Liver Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Neuroblastoma - Pipeline Insight, 2024 - Product Thumbnail Image

Neuroblastoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Osteosarcoma - Pipeline Insight, 2024 - Product Thumbnail Image

Osteosarcoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2024 - Product Thumbnail Image

CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
Synovial Sarcoma Pipeline Analysis Report - Product Thumbnail Image

Synovial Sarcoma Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Gastric Cancer Pipeline Analysis Report - Product Thumbnail Image

Gastric Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
Loading Indicator

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells. CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors. CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more